Publications by authors named "Cor van der Leest"

Claim this Profile
T
The effectiveness of pembrolizumab maintenance with or without pemetrexed after induction treatment for advanced non-squamous Non-Small-Cell Lung cancer.
Bas Jm Peters, Esmée van Geffen, Doranne Hilarius, Stephan Böhringer, Juliëtte Zwaveling, Cor H van der Leest

Lung Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating Tumor DNA in Advanced EGFRex20+ NSCLC: Concordance with Tissue Biopsy, Monitoring of Response, and Resistance to High-Dose Osimertinib.
Fenneke Zwierenga, M Benthe Muntinghe-Wagenaar, Pim Rozendal, Adrianus J de Langen, Lizza E L Hendriks, Cor van der Leest, Paul van der Leest

Target Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Toxicity Profile of Pemetrexed in Non-Small Cell Lung Cancer Patients With Moderate Renal Impairment: A Retrospective Cohort Study.
Mart P Kicken, Rob Ter Heine, Intissar Azarfane, Nikki de Rouw, Fenna de Vries, Cor H van der Leest

Clin Lung Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bronchiolitis after Combination Immunotherapy With Ipilimumab and Nivolumab in a Melanoma Patient.
Shahir Basir, Jana Bosiers, Hans M Westgeest, David C Y Yick, Jochem R van Werven, Cor H van der Leest

J Immunother· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the impact of patient-specific clinical features on osimertinib effectiveness in a real-world cohort of patients with EGFR mutated non-small cell lung cancer.
Ard van Veelen, G D Marijn Veerman, Marjon V Verschueren, Judith L Gulikers, Christi M J Steendam, Cor van der Leest

Int J Cancer· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer.
Rob Ter Heine, Michel M van den Heuvel, Berber Piet, Maarten J Deenen, Anthonie J van der Wekken, Cor H van der Leest

Target Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of Bone Metastases and Skeletal-Related Events in Patients With -Mutated NSCLC Treated With Osimertinib.
Anita J W M Brouns, Ard van Veelen, G D Marijn Veerman, Christi Steendam, Safiye Dursun, Cor van der Leest

JTO Clin Res Rep· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Outcomes of Patients With Metastatic NSCLC After Discontinuation of Immunotherapy Because of Immune-Related Adverse Effects.
Lysanne A Lievense, Peter Heukels, Nico C van Walree, Cor H van der Leest

JTO Clin Res Rep· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The course of C-peptide levels in patients developing diabetes during anti-PD-1 therapy.
Edwin A Basak, Karlijn de Joode, Tom J J Uyl, Ronald van der Wal, Marco W J Schreurs, Cor H van der Leest

Biomed Pharmacother· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of esomeprazole on the bioavailability of afatinib: A pharmacokinetic cross-over study in patients with non-small cell lung cancer.
G D Marijn Veerman, Daan P Hurkmans, Marthe S Paats, Esther Oomen-de Hoop, Cor H van der Leest

Biomed Pharmacother· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial.
Fenneke Zwierenga, Bianca van Veggel, Lizza E L Hendriks, T Jeroen N Hiltermann, Birgitta I Hiddinga, Cor van der Leest

Lung Cancer· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving the tolerability of osimertinib by identifying its toxic limit.
Bram C Agema, G D Marijn Veerman, Christi M J Steendam, Daan A C Lanser, Tim Preijers, Cor van der Leest

Ther Adv Med Oncol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The development of the ADO-SQ model to predict 1-year mortality in patients with COPD.
Catherine Owusuaa, Cor van der Leest, Gea Helfrich, Roxane Heller-Baan, Cj van Loenhout

Palliat Med· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA).
Ivan O Rosas, Norbert Bräu, Michael Waters, Ronaldo C Go, Atul Malhotra, Cor H van der Leest

EClinicalMedicine· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial.
Jennifer Tom, Min Bao, Larry Tsai, Aditi Qamra, David Summers, Cor H van der Leest

Crit Care Med· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium.
Karlijn de Joode, Jolien Tol, Paul Hamberg, Marissa Cloos, Elisabeth A Kastelijn, Cor H van der Leest

Eur J Cancer· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic polymorphism in is associated with effectiveness and toxicity of pemetrexed in non-small-cell lung cancer.
Sabine Visser, Stijn Koolen, Nadine van Donk, Nico van Walree, Cor van der Leest

Thorax· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study.
Melissa L Johnson, Zanete Zvirbule, Konstantin Laktionov, Aslaug Helland, Byoung Chul Cho, Cor van der Leest

J Thorac Oncol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors.
Daan P Hurkmans, Sebastiaan D T Sassen, Karlijn de Joode, Lisanne Putter, Edwin A Basak, Cor H Van der Leest

J Immunother Cancer· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of Cow's Milk and Esomeprazole on the Absorption of Erlotinib: A Randomized, Crossover Pharmacokinetic Study in Lung Cancer Patients.
G D Marijn Veerman, Koen G A M Hussaarts, Robert Peric, Esther Oomen-de Hoop, Kersten D Landa, Cor H van der Leest

Clin Pharmacokinet· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preoperative mediastinal staging in patients with cT1-3NxM0 non-small cell lung cancer.
Bastiaan E Steunenberg, Tom P A Beddows, Hans G W De Groot, Ninos Ayez, Cor Van Der Leest

Thorac Cancer· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma Predictive Features in Treating EGFR-Mutated Non-Small Cell Lung Cancer.
Christi M J Steendam, G D Marijn Veerman, Melinda A Pruis, Peggy Atmodimedjo, Marthe S Paats, Cor van der Leest

Cancers (Basel)· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer.
Daan P Hurkmans, Edwin A Basak, Nina Schepers, Esther Oomen-De Hoop, Cor H Van der Leest

J Immunother Cancer· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma Cell-Free DNA Testing of Patients With EGFR Mutant Non-Small-Cell Lung Cancer: Droplet Digital PCR Versus Next-Generation Sequencing Compared With Tissue-Based Results.
Christi M J Steendam, Peggy Atmodimedjo, Evert de Jonge, Marthe S Paats, Cor van der Leest

JCO Precis Oncol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients.
Daan P Hurkmans, Edwin A Basak, Tanja van Dijk, Darlene Mercieca, Marco W J Schreurs, Cor H van der Leest

J Immunother Cancer· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis